Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
Med Progress LLC has 2 pending office actions in the Biotechnology & Pharmaceuticals technology area. The portfolio's active cases are handled by 2 distinct examiners across multiple art units. Erin M Bowers is the busiest examiner for the company, with 1 pending office action. This spread across different examiners suggests that the company's biotechnology interests cover multiple specialized sub-fields.
The presence of 2 distinct art units indicates that the applications are categorized into different technical groups at the patent office. For practitioners, this distribution requires managing distinct prosecution timelines and examiner expectations across the biotechnology sector. The lack of concentration in a single art unit reflects a diversified approach to the company's current pharmaceutical and biological intellectual property developments.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (50%) |
| Double-patenting + other | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| BOWERS, ERIN M | 1 | 54.7% | +10.6% |
| BREEN, KIMBERLY CATHERINE | 1 | 23.8% | +56.9% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18392498 | Reducing or Inhibiting Ocular Damage by Hyaluronidase Administration | BREEN, KIMBERLY CATHERINE | 29d overdue |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18392498 | Reducing or Inhibiting Ocular Damage by Hyaluronidase Administration | BREEN, KIMBERLY CATHERINE | 29d overdue |
| 18693468 | Reducing or Inhibiting Tissue Damage Using Hyaluronidase Administration | BOWERS, ERIN M | 3d overdue |
| Art Unit | Apps |
|---|---|
| 1653 | 1 |
| 1657 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18693468 | Reducing or Inhibiting Tissue Damage Using Hyaluronidase Administration | BOWERS, ERIN M | 1653 | §103DP | Final Rejection | 3d overdue | Pending | Mar 19, 2024 |
| 18392498 | Reducing or Inhibiting Ocular Damage by Hyaluronidase Administration | BREEN, KIMBERLY CATHERINE | 1657 | §103 | Final Rejection | 29d overdue | Pending | Dec 21, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial